Indian stocks: Visit www.stage2stocks.com →

Achieve Life Sciences, Inc.

Stage 2 · Advancing · week 23

As of Oct 22, 2026, Achieve Life Sciences is in Stage 2, the uptrend phase, now in week 23 (since May 11, 2026). It closed at $6.50, 23.8% below its 52-week high and above its 200-day average, which is rising.

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. More about the company

$6.50
-0.15% today
$670M · Small cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is ACHV early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 25w
S2 18w
S2 24w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S3 3w → S4 12w → S1 6w → S4 1w → S1 3w → S4 5w → S1 5w → S4 3w → S1 1w → S2 12w → S3 3w → S4 6w → S1 3w → S2 5w → S3 1w → S4 25w → S1 9w → S4 6w → S1 4w → S2 18w → S3 11w → S1 1w → S2 24w current
Total tracked: 166 weeks across 23 stage runs.

ACHV among Biotechnology123rd of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…123ACHVStage 2 · wk 2374−17.0%
vs 52W High
-23.8%
$2.65 lo$8.53 hi
23.8% below 52W high, deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 23
1w13w26w
Week 23, proven structure
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
16.0%
200 DMA: $5.60 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.62x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-17.0%
3M
+6.6%
6M
+56.6%
YTD
+30.8%
1Y
+26.2%
Scan Membership
Breakout Watch
Latest: 2024-11-05
7 appearances in last 60 days. First seen: 2019-04-09.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 23 · Vol 0.62x
2026-10-21S2
Wk 23 · Vol 1.42x
2026-10-20S2
Wk 23 · Vol 1.38x
2026-10-19S2
Wk 23 · Vol 0.54x
2026-10-16S2
Wk 23 · Vol 1.33x
2026-10-15S2
Wk 22 · Vol 0.80x
2026-10-14S2
Wk 22 · Vol 1.10x
2026-10-13S2
Wk 22 · Vol 1.12x
2026-10-12S2
Wk 22 · Vol 0.64x
2026-10-09S2
Wk 22 · Vol 0.67x
2026-10-08S2
Wk 21 · Vol 0.75x
2026-10-07S2
Wk 21 · Vol 0.70x
Moving averages & range
50 DMA
$7.56
200 DMA
$5.60
52W High
$8.53
52W Low
$2.65
5D Low
$6.38
Resistance levels (recent highs)
20d High
$8.09
60d High
$8.53
120d High
$8.53
250d High
$8.53
Next resistance
+24.5%
to 20d High
ROE
-845.0%
Profit margin 0.0%
Dividend Yield
0.00%
P/B -45.5

Achieve Life Sciences: quick answers

What stage is Achieve Life Sciences in?

As of Oct 22, 2026, Achieve Life Sciences (ACHV) is in Stage 2, the uptrend phase. It entered Stage 2 on May 11, 2026 and is in week 23. What the four stages mean

Is Achieve Life Sciences in an uptrend?

Yes. Achieve Life Sciences is in a Stage 2 uptrend. It trades 16.0% above its 200-day average, which is rising.

How far is Achieve Life Sciences from its 52-week high?

Achieve Life Sciences closed at $6.50 on Oct 22, 2026, 23.8% below its 52-week high of $8.53. Its 52-week low is $2.65.

How has Achieve Life Sciences performed over the past year?

As of Oct 22, 2026, Achieve Life Sciences is up 26.2% over the past year and up 30.8% so far in 2026.

Which sector and industry is Achieve Life Sciences in?

Achieve Life Sciences is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.